ALN-4324 (GRB14) Investigational RNAi therapy targeting GRB14 in Phase 2 development for type 2 diabetes mellitus, extending Alnylam’s clinical portfolio into metabolic disease.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-4324 (GRB14).
Add it to your Products I use list and share why you use it.